A study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects.
This study is checking how a new medicine, called ASN51, behaves in the body when a healthy person takes it along with other common medicines. These other medicines include things like fluvoxamine, itraconazole, and paroxetine. The main goal is to see if these common medicines change how ASN51 is used, broken down, or removed from the body. This is a very early stage study, often called a 'Phase I' trial. It's an important step to make sure that if ASN51 goes on to be used as a treatment, doctors will know how it might interact with other drugs people might be taking. It helps ensure future patient safety.
At a glance
What is this study about?
This research study is trying to understand how a new medicine, called ASN51, works inside the body when it's taken at the same time as some other common medicines. Think of it like this: when you take a new medicine, your body has natural ways to process it, clear it out, and make it work. Sometimes, if you take two different medicines together, one can affect how the other is processed.
The medicines being looked at in this study are fluvoxamine, itraconazole, and paroxetine. These are not new drugs; they are used for various conditions. Scientists know that these specific drugs can affect how other medicines are handled by the body's systems. By giving ASN51 along with these known drugs, the researchers can see if and how ASN51's journey through the body changes. This is important information for how ASN51 might be used safely in the future.
This is a very early stage of testing for ASN51, often called a 'Phase I' study. It's done with healthy volunteers, not people who are unwell. The main purpose is to learn about the new medicine's basic behaviour and safety, not to treat any specific illness. The results will help doctors understand how ASN51 might interact with other everyday medications, which is crucial for patient safety if ASN51 ever becomes a widely used treatment for conditions like proteinopathies (problems linked to certain proteins in the body).
Key takeaways
- This study is examining how a new drug, ASN51, interacts with common medicines.
- It's an early-stage study (Phase I) for healthy adult volunteers.
- The goal is to understand how ASN51 is processed in the body when taken with other drugs.
- Results will help ensure future patient safety if ASN51 becomes a wider treatment.
- Taking part involves clinic visits, blood tests, and taking study medications.
Who may be eligible?
This study is looking for healthy adults aged 18 and over. It's open to both men and women.
Because this is a study about how medicines interact, the researchers will need to make sure you're not taking any other medications that could interfere with the results, unless they are specifically part of the study design. They will also check your overall health to ensure it's safe for you to take part.
It's important to remember that 'healthy' in a research study means you don't have any major ongoing health conditions that could affect how your body processes the study drugs or put you at risk. The study team will explain all the specific health checks they will perform.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally in good health?
- Are you comfortable with taking new medications as part of a study?
- Are you able to attend several clinic visits, possibly with overnight stays?
- Are you willing to have blood tests done regularly?
What does participation involve?
If you decide to take part, you would receive the new medicine, ASN51, and then, at different times, you would also receive one of the specific common medicines (fluvoxamine, itraconazole, or paroxetine) as directed by the study team. You would have several visits to a clinic or research unit. During these visits, there would be blood tests to measure the levels of the medicines in your body, and possibly urine tests and other general health checks like blood pressure and heart rate.
The total amount of time you would be involved in the study would depend on how many different ways they are testing the medicines, but typically, these kinds of studies involve several days or weeks of participation, with some overnight stays at the clinic possible. You would be given a detailed schedule before you agree to participate.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What are 'Proteinopathies'?
Proteinopathies are a group of diseases where certain proteins in the body don't fold correctly, which can cause problems in cells and tissues. This study isn't directly treating these, but ASN51 might be a future treatment for them.
What does 'Human Pharmacology (Phase I)' mean?
It means this is a very early stage study in people. The main goals are to check if the new medicine is safe and to understand how it behaves in the body, not to see if it treats a specific illness yet.
Will I get paid for taking part?
Many early-stage studies like this offer payment for your time, effort, and any travel expenses. This will be clearly explained to you before you agree to participate.
Why use 'healthy subjects' instead of people with an illness?
Using healthy volunteers at this early stage helps researchers understand the basic safety and how the drug works in a 'normal' body, without other illnesses or medicines complicating the results.
What are fluvoxamine, itraconazole, and paroxetine?
These are common prescription medicines. Fluvoxamine and paroxetine are often used for mood or anxiety conditions, and itraconazole is an antifungal medicine used to treat infections.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.